Home > Business > Industry

SK bioscience's flu vaccine gets green light from Indonesia

Published: 23 Oct. 2024, 15:45 Updated: 23 Oct. 2024, 15:49

LEE JAE-LIM
[email protected]

SK bioscience's cell-cultured influenza vaccine SKYCellflu [SK BIOSCIENCE]

SK bioscience has received the green light from an Indonesian regulator to export its self-developed influenza vaccine, the first time a domestically developed flu vaccine has received approval in the country.

SKYCellflu, the biotech company’s cell-cultured influenza vaccine, was verified by Indonesia’s Food and Drug Authority, Badan Pengawas Obat dan Makanan, it said on Wednesday.

The pharmaceutical firm sees significant potential to be tapped into the Indonesian market, given its vast geography and large population.

The country spans across the northern and southern hemisphere, which means that it is influenced by the World Health Organization’s (WHO) flu vaccination guidelines for both regions and thus needs a stable year-round supply.

Indonesia's influenza vaccine market is projected to grow to $69.1 million in 2030 from 2022’s $38.5 million, according to market researcher Innsight10.

SKYCellflu is the world's first cell culture-based influenza vaccine to obtain WHO prequalification certification, according to the company, which means the vaccine has been certified for safety and efficacy under strict evaluation of the manufacturing process, quality and clinical trial results by the global health organization.

The vaccine has received approval in multiple Asian countries, including Malaysia, Thailand, Myanmar, Iran, Singapore, Pakistan, Mongolia and Brunei. Last year, the vaccine was licensed in Chile, marking its entrance into the South American market.

BY LEE JAE-LIM [[email protected]]